6.1
A phase III trial of entecavir plus tenofovir disoproxil combination therapy versus entecavir monotherapy in treatment-naive people with chronic hepatitis B is currently recruiting participants.
6 Recommendations for further research
6.2
Research on the long-term risk of resistance with tenofovir disoproxil monotherapy and tenofovir disoproxil in combination with other antiviral agents is needed because few RCTs are currently available.